Regina A. Swift

2.6k total citations
103 papers, 2.0k citations indexed

About

Regina A. Swift is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Regina A. Swift has authored 103 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Hematology, 51 papers in Molecular Biology and 48 papers in Oncology. Recurrent topics in Regina A. Swift's work include Multiple Myeloma Research and Treatments (88 papers), Protein Degradation and Inhibitors (34 papers) and Peptidase Inhibition and Analysis (30 papers). Regina A. Swift is often cited by papers focused on Multiple Myeloma Research and Treatments (88 papers), Protein Degradation and Inhibitors (34 papers) and Peptidase Inhibition and Analysis (30 papers). Regina A. Swift collaborates with scholars based in United States, Switzerland and France. Regina A. Swift's co-authors include James R. Berenson, Robert Vescio, Ori Yellin, Russell Mapes, Youram Nassir, Blake Morrison, Ralph V. Boccia, Tanya M. Spektor, Haiming Chen and Mingjie Li and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Regina A. Swift

100 papers receiving 2.0k citations

Peers

Countries citing papers authored by Regina A. Swift

Since Specialization

Citations

This map shows the geographic impact of Regina A. Swift's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Regina A. Swift with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Regina A. Swift more than expected).

Fields of papers citing papers by Regina A. Swift

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Regina A. Swift. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Regina A. Swift. The network helps show where Regina A. Swift may publish in the future.

Co-authorship network of co-authors of Regina A. Swift

This figure shows the co-authorship network connecting the top 25 collaborators of Regina A. Swift. A scholar is included among the top collaborators of Regina A. Swift based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Regina A. Swift. Regina A. Swift is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone 2023 ·Blood ·James R. Berenson, (unknown), Stephanie R. Rice, (unknown), Ralph V. Boccia, (unknown), Mehdi M. Moezi, Stephen Lim, Gary K. Schwartz, Shahrooz Eshaghian, Matthew Brobeck, Regina A. Swift, (unknown), Sean Bujarski, (unknown), (unknown), (unknown), Robert Vescio	1
2	Loss of anti‐spike antibodies following mRNA vaccination for COVID‐19 among patients with multiple myeloma 2023 ·Cancer Reports ·Samuel D. Stampfer, Sean Bujarski, (unknown), (unknown), (unknown), (unknown), Ning Xu, Mingjie Li, (unknown), Regina A. Swift, (unknown), Shahrooz Eshaghian, James R. Berenson	2
3	A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen 2022 ·Experimental Hematology ·(unknown), (unknown), Tanya M. Spektor, (unknown), Jacob D. Bitran, (unknown), Mehdi M. Moezi, Alberto Bessudo, John Hrom, Shahrooz Eshaghian, Regina A. Swift, (unknown), (unknown), Stephen Lim, James R. Berenson	2
4	A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma 2020 ·Clinical Cancer Research ·James R. Berenson, (unknown), Tanya M. Spektor, (unknown), (unknown), (unknown), (unknown), (unknown), Regina A. Swift, Gary K. Schwartz, Shahrooz Eshaghian, Laura Stampleman, Robert A. Moss, Stephen Lim, Robert Vescio	25
5	Removal of a Silicone Gel Breast Implant in a Multiple Myeloma Patient Improved Disease Status: A Case Report 2020 ·Case Reports in Oncology ·(unknown), James Wang, Regina A. Swift, (unknown), Tanya M. Spektor, James R. Berenson	2
6	Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranuloma Associated With Multiple Myeloma 2020 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), Regina A. Swift, (unknown), (unknown), Tanya M. Spektor, James R. Berenson	2
7	Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Multiple Myeloma Patients Undergoing New Treatments 2017 ·Blood ·Sean Bujarski, Kyle A. Udd, Camilia Soof, Haiming Chen, Mingjie Li, Eric Sanchez, Joshua Stern, Cathy S. Wang, (unknown), Regina A. Swift, (unknown), (unknown), James R. Berenson	1
8	Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib 2016 ·Annals of Hematology ·(unknown), Suzie Vardanyan, (unknown), James Wang, Nika M Harutyunyan, (unknown), (unknown), Tanya M. Spektor, Kyle A. Udd, Shahrooz Eshaghian, Youram Nassir, (unknown), Regina A. Swift, James R. Berenson	14
9	Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients 2016 ·Haematologica ·(unknown), Mingjie Li, Suzie Vardanyan, Nika M Harutyunyan, (unknown), (unknown), Tanya M. Spektor, Claudia Andreu‐Vieyra, (unknown), Eric Sanchez, Kyle A. Udd, Cathy S. Wang, Regina A. Swift, Haiming Chen, James R. Berenson	140
10	Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic 2016 ·Annals of Hematology ·(unknown), Suzie Vardanyan, (unknown), James Wang, Nika M Harutyunyan, (unknown), (unknown), Tanya M. Spektor, Kyle A. Udd, Shahrooz Eshaghian, Youram Nassir, (unknown), Regina A. Swift, James R. Berenson	6
11	Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy 2014 ·Leukemia ·James R. Berenson, James Hilger, Ori Yellin, Robert Dichmann, Dipti Patel‐Donnelly, Ralph V. Boccia, Alberto Bessudo, Laura Stampleman, Donald Gravenor, Shahrooz Eshaghian, Youram Nassir, Regina A. Swift, Robert Vescio	55
12	A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma 2014 ·Supportive Care in Cancer ·James R. Berenson, Ori Yellin, (unknown), Chien-Shing Chen, Veena Charu, Thomas Woliver, (unknown), (unknown), Youram Nassir, Regina A. Swift, Claudia Andreu‐Vieyra, Robert Vescio	27
13	A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma 2013 ·Annals of Hematology ·James R. Berenson, James Hilger, Ori Yellin, Ralph V. Boccia, Jeffrey Matous, (unknown), Hassan Ghazal, (unknown), Edwin Kingsley, Wael A. Harb, Stephen J. Noga, Youram Nassir, Regina A. Swift, Robert Vescio	34
14	A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients 2011 ·British Journal of Haematology ·James R. Berenson, Ori Yellin, (unknown), Ravi Patel, Alberto Bessudo, Ralph V. Boccia, Hank H. Yang, Robert Vescio, Elizabeth Yung, Russell Mapes, (unknown), James Hilger, (unknown), (unknown), Youram Nassir, Regina A. Swift	25
15	Metatarsal Stress Fractures in Patients with Multiple Myeloma Treated with Long-Term Bisphosphonates 2011 ·Journal of Bone and Joint Surgery ·Gabriel N. Waterman, Ori Yellin, (unknown), Regina A. Swift, (unknown), (unknown), James R. Berenson	11
16	A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma 2010 ·Annals of Hematology ·Gabriel N. Waterman, Ori Yellin, Regina A. Swift, Russell Mapes, (unknown), (unknown), James R. Berenson	12
17	Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm study 2006 ·British Journal of Haematology ·James R. Berenson, Ralph V. Boccia, David S. Siegel, Marek J. Bozdech, Alberto Bessudo, Edward A. Stadtmauer, (unknown), Ronald G. Steis, Marshall S. Flam, Jose Lutzky, (unknown), (unknown), Siu‐Fun Wong, Robert A. Moss, Ravi Patel, (unknown), (unknown), (unknown), Howard Yeh, Regina A. Swift	64
18	A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients with Relapsed or Refractory Multiple Myeloma 2004 ·Clinical Lymphoma ·James R. Berenson, Regina A. Swift, (unknown), Matthew B. Purner	7
19	Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases 2002 ·The Journal of Clinical Pharmacology ·Tianling Chen, James R. Berenson, Robert Vescio, Regina A. Swift, (unknown), Susan Goodin, Patricia LoRusso, Peiming Ma, Christina Ravera, (unknown), Horst Schran, John J. Seaman, Andrej Skerjanec	310
20	A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease 2001 ·Cancer ·James R. Berenson, Robert Vescio, (unknown), Carol Y. Nishikubo, Matthew B. Rettig, Regina A. Swift, Francisco Conde, (unknown)	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact